PARTNER 3 Trial - Aortic Valve-in-Valve
← catalyst calendarNCT03003299 · readout ≤ 2,357 d
Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
125estimated
Sites
51
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-01-05 | actual | When the study began enrolling |
| Primary completion | Jan 2033 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2038 | estimated | The whole study's end, after follow-up |
| First posted | 2016-12-28 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-05-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Aortic Stenosis
- Aortic Stenosis, Severe
Intervention
- Device: Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Primary outcome
what the primary-completion date above is the date OFSafety and Effectiveness - Non-hierarchical composite of all-cause mortality and stroke
measured 1 year
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed